Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 1998

View Archived Issues

Inex R&D pipeline update

Cellegy and 3M combine technologies

CoCensys initiates phase II migraine study with ganaxolone tablets

Orphan drug status granted to Endorex's ImmTher for Ewing's sarcoma

SciClone's lead cystic fibrosis drug found safe in phase I

Elan completes acquisition of Carnrick

Neuprex receives orphan drug designation for treatment of severe meningococcal disease

rAd-p53 in gene therapy of cancers with p53 mutation; overview of gene therapies in development

Schering-Plough acquires Canadian rights to Ribi's melanoma theraccine

VIMRx updates stockholders at annual meeting

Ventana Genetics reports novel method for identification of drug target sites

Melphalan derivative pinpointed for further study

Biovail granted license to Celgene's ADHD treatment

New class of FPTase inhibitors discovered at Merck & Co.

Astra prepares another series of immunomodulatory peptides

Tricyclic antitumor compounds developed at Schering-Plough

Modulators of drug/multidrug resistance from Lilly

RPR acquires worldwide rights to Novartis anticoagulant

Phase II trial with HGP-30W HIV vaccine begins in The Netherlands

Elan/Neurex merger nears completion

Antisense therapy for CMV retinitis receives priority review status from FDA

Roche reviews HIV product pipeline in time for AIDS conference

Amur's AM-454 blocks progression of type II diabetes in preclinical studies

Preclinical studies with doranidazole summarized

Two-year landmark study demonstrates importance of initiating triple therapy simultaneously

Pyrazoloacridine evaluated in patients with pancreatic and hepatobiliary cancer

Various schedules and doses of DMDC explored in phase I

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...